ID   TihoDProAdcarc1258
AC   CVCL_W737
SY   CT1258; CT-1258; Adcarc1258
DR   GEO; GSM4962601
DR   GEO; GSM4962602
DR   GEO; GSM4962603
DR   GEO; GSM4962604
DR   GEO; GSM4962605
DR   GEO; GSM4962606
DR   GEO; GSM4962607
DR   GEO; GSM4962608
DR   GEO; GSM4962609
DR   Wikidata; Q28872894
RX   PubMed=15994418;
RX   PubMed=18706092;
RX   PubMed=24324078;
RX   PubMed=24914948;
RX   PubMed=26774145;
RX   PubMed=32168360;
RX   PubMed=32368185;
RX   PubMed=35109825;
CC   Doubling time: 21.6 hours (PubMed=32168360); 29.2 hours (PubMed=32368185).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Prostate; UBERON=UBERON_0002367.
CC   Breed/subspecies: Briard; VBO=VBO_0200234.
DI   NCIt; C128122; Canine prostate carcinoma
OX   NCBI_TaxID=9615; ! Canis lupus familiaris (Dog)
SX   Male
AG   10Y
CA   Cancer cell line
DT   Created: 17-07-14; Last updated: 10-09-24; Version: 11
//
RX   PubMed=15994418; DOI=10.1093/jhered/esi085;
RA   Winkler S., Murua Escobar H., Eberle N., Reimann-Berg N., Nolte I.,
RA   Bullerdiek J.;
RT   "Establishment of a cell line derived from a canine prostate carcinoma
RT   with a highly rearranged karyotype.";
RL   J. Hered. 96:782-785(2005).
//
RX   PubMed=18706092; DOI=10.1186/1471-2407-8-240; PMCID=PMC2527616;
RA   Fork M.A.M., Murua Escobar H., Soller J.T., Sterenczak K.A.,
RA   Willenbrock S., Winkler S., Dorsch M., Reimann-Berg N., Hedrich H.J.,
RA   Bullerdiek J., Nolte I.;
RT   "Establishing an in vivo model of canine prostate carcinoma using the
RT   new cell line CT1258.";
RL   BMC Cancer 8:240.1-240.8(2008).
//
RX   PubMed=24324078;
RA   Moulay M., Liu W., Willenbrock S., Sterenczak K.A., Carlson R.,
RA   Ngezahayo A., Murua Escobar H., Nolte I.;
RT   "Evaluation of stem cell marker gene expression in canine prostate
RT   carcinoma- and prostate cyst-derived cell lines.";
RL   Anticancer Res. 33:5421-5431(2013).
//
RX   PubMed=24914948; DOI=10.1371/journal.pone.0098788; PMCID=PMC4051699;
RA   Willenbrock S., Wagner S., Reimann-Berg N., Moulay M.,
RA   Hewicker-Trautwein M., Nolte I., Murua Escobar H.;
RT   "Generation and characterisation of a canine EGFP-HMGA2 prostate
RT   cancer in vitro model.";
RL   PLoS ONE 9:E98788-E98788(2014).
//
RX   PubMed=26774145; DOI=10.4149/208_150924N505;
RA   Hammer S.C., Nagel S., Junginger J., Hewicker-Trautwein M., Wagner S.,
RA   Heisterkamp A., Ngezahayo A., Nolte I., Murua Escobar H.;
RT   "Claudin-1, -3, -4 and -7 gene expression analyses in canine prostate
RT   carcinoma and mammary tissue derived cell lines.";
RL   Neoplasma 63:231-238(2016).
//
RX   PubMed=32168360; DOI=10.1371/journal.pone.0230272; PMCID=PMC7069630;
RA   Packeiser E.-M., Hewicker-Trautwein M., Thiemeyer H., Mohr A.,
RA   Junginger J., Schille J.T., Murua Escobar H., Nolte I.;
RT   "Characterization of six canine prostate adenocarcinoma and three
RT   transitional cell carcinoma cell lines derived from primary tumor
RT   tissues as well as metastasis.";
RL   PLoS ONE 15:E0230272-E0230272(2020).
//
RX   PubMed=32368185; DOI=10.1186/s12935-020-01211-0; PMCID=PMC7189542;
RA   Liu W., Sender S., Kong W.-B., Beck J., Sekora A., Bornemann-Kolatzki K.,
RA   Schutz E., Junghanss C., Brenig B., Nolte I., Murua Escobar H.;
RT   "Establishment and characterization of stable red, far-red (fR) and
RT   near infra-red (NIR) transfected canine prostate cancer cell lines.";
RL   Cancer Cell Int. 20:139.1-139.11(2020).
//
RX   PubMed=35109825; DOI=10.1186/s12935-021-02422-9; PMCID=PMC8812184;
RA   Packeiser E.-M., Taher L., Kong W.-B., Ernst M., Beck J.,
RA   Hewicker-Trautwein M., Brenig B., Schutz E., Murua Escobar H.,
RA   Nolte I.;
RT   "RNA-seq of nine canine prostate cancer cell lines reveals diverse
RT   therapeutic target signatures.";
RL   Cancer Cell Int. 22:54.1-54.21(2022).
//